Marcelo Teixeira de Holanda

Marcelo Teixeira de Holanda

Auto-generated profile, based on publicly available information

Marcelo Teixeira de Holanda

Clinical Research Laboratory in Chagas Disease Oswaldo Cruz Foundation, Fiocruz, Evandro Chagas National Institute of Infectious Diseases Rio de Janeiro Rio de Janeiro Brazil

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Revista da Sociedade Brasileira de Medicina Tropical
Verified
Journal Article
Open access
AHAlejandro Marcel Hasslocher-Moreno
Alejandro Marcel Hasslocher-Moreno
RSRoberto M Saraiva
Roberto M Saraiva
PBPedro Emmanuel Alvarenga Americano do Brasil
Pedro Emmanuel Alvarenga Americano do Brasil
LSLuiz Henrique Conde Sangenis
Luiz Henrique Conde Sangenis
SXSergio Salles Xavier
Sergio Salles Xavier
MMMauro Felippe Felix Mediano
Mauro Felippe Felix Mediano
We aimed to describe the sociodemographic, epidemiological, and clinical characteristics of patients with chronic Chagas disease (CD) at an infectious disease referral center. Changes in patient profiles over time were also evaluated. This retrospective study included patients with CD from November 1986-December 2019. All patients underwent an evaluation protocol that included sociodemographic profile; epidemiological history; anamnesis; and physical, cardiologic, and digestive examinations. Trend differences for each 5-year period from 1986 to 2019 were tested using a nonparametric trend test for continuous and generalized linear models with binomial distribution for categorical variables. A total of 2,168 patients (52.2% women) were included, with a mean age of 47.8 years old. White patients with low levels of education predominated. The reported transmission mode was vectorial in 90.2% of cases. The majority came from areas with a high prevalence (52.2%) and morbidity (67.8%) of CD. The most common clinical presentation was the indeterminate form (44.9%). The number of patients referred gradually decreased and the age at admission increased during the study period, as did the patients' levels of education. The clinical profile of CD is characterized by a predominance of the indeterminate form of the disease. Regarding the patients who were followed up at the referral center, there was a progressive increase in the mean age and a concomitant decrease in the number of new patients. This reflects the successful control of vector and transfusion transmission in Brazil as well as the aging population of patients with CD.

1 November 2020 in Journal of the American Society of Echocardiography
Verified
Journal Article
Closed access
RSRoberto M Saraiva
Roberto M Saraiva
NPNicole P. Pacheco
Nicole P. Pacheco
TPThayanne O.J.S. Pereira
Thayanne O.J.S. Pereira
ACAndréa R. Costa
Andréa R. Costa
MHMarcelo T. Holanda
Marcelo T. Holanda
HVHenrique H. Veloso
Henrique H. Veloso

Verified
Journal Article
Open access
PDF file
AHAlejandro Marcel Hasslocher-Moreno
Alejandro Marcel Hasslocher-Moreno
SXSergio Salles Xavier
Sergio Salles Xavier
RSRoberto M Saraiva
Roberto M Saraiva
LSLuiz Henrique Conde Sangenis
Luiz Henrique Conde Sangenis
MHMarcelo Teixeira de Holanda
Marcelo Teixeira de Holanda
Andrea Silvestre de SousaAndrea Silvestre de Sousa
Andrea Silvestre de Sousa
Most patients with chronic Chagas disease (CD) present the indeterminate form and are at risk to develop the cardiac form. However, the actual rate of progression to the cardiac form is still unknown. Methods: In total, 550 patients with the indeterminate CD form were followed by means of annual electrocardiogram at our outpatient clinic. The studied endpoint was progression to cardiac form defined by the appearance of electrocardiographic changes typical of CD. The progression rate was calculated as the cumulative progression rate and the incidence progression rate per 100 patient years. Results: Thirty-seven patients progressed to the CD cardiac form within a mean of 73 ± 48 months of follow-up, which resulted in a 6.9% cumulative progression rate and incidence rate of 1.48 cases/100 patient years. Patients who progressed were older (mean age 47.8 ± 12.2 years), had a higher prevalence of associated heart diseases (p < 0.0001), positive xenodiagnosis (p = 0.007), and were born in the most endemic Brazilian states (p = 0.018). Previous co-morbidities remained the only variable associated with CD progression after multivariate Cox proportional hazards regression analysis (p = 0.002). Conclusion: The progression rate to chronic CD cardiac form is low and inferior to rates previously reported in other studies.

20 June 2023 in Journal of the American Heart Association
Verified
Journal Article
Open access
VMVeronica G. Mendes
Veronica G. Mendes
LRLorena Rimolo
Lorena Rimolo
ALAna Carolina B. de Lima
Ana Carolina B. de Lima
RFROBERTO RODRIGUES FERREIRA
ROBERTO RODRIGUES FERREIRA
LOLuciano S. Oliveira
Luciano S. Oliveira
RSRoberto M Saraiva
Roberto M Saraiva
Background: Chagas disease (CD) presents an ominous prognosis. The predictive value of biomarkers and new echocardiogram parameters in adjusted models have not been well studied. Methods and Results: There were 361 patients with chronic CD (57.6% men, 61±11 years of age, clinical forms: indeterminate 27.1%, cardiac 56.6%, digestive 3.6%, cardiodigestive 12.7%) included in this single‐center, observational, prospective longitudinal study. Echocardiographic evaluation included strain analyses of left atrial, left ventricular (LV), and right ventricular and 3‐dimensional analyses of left atrial and LV volumes. Biomarkers included cardiac troponin I, brain natriuretic peptide, transforming growth factor β1, tumor necrosis factor, matrix metalloproteinases, and Trypanosoma cruzi polymerase chain reaction. The studied end point was a composite of CD‐related mortality, heart transplant, hospital admission due to worsening heart failure, or new cardiac device insertion. Event‐free survival was analyzed by multivariable regression analyses adjusted for competing risks. P values <0.05 were considered significant. The composite event occurred in 79 patients after 4.9±2.0 years follow‐up. LV end‐diastolic volume (hazard ratio [HR], 1.01 [95% CI, 1.00–1.02]; P =0.02), peak negative global atrial strain (HR, 1.08 [95% CI, 1.00–1.17]; P =0.04), LV global circumferential strain (HR, 1.12 [95% CI, 1.04–1.21]; P =0.003), LV torsion (HR, 0.55 [95% CI, 0.35–0.81]; P =0.003), brain natriuretic peptide (HR, 2.03 [95% CI, 1.23–3.34]; P =0.005), and positive T cruzi polymerase chain reaction (HR, 1.80 [95% CI, 1.12–2.91]; P =0.01) were end point predictors independent from age, sex, 2‐dimensional echocardiographic indexes, hypertension, previous cardiac device, and CD cardiac form. Conclusions: Two‐dimensional strain‐ and 3‐dimensional‐derived parameters, brain natriuretic peptide, and positive T cruzi polymerase chain reaction can be useful for prediction of CD cardiovascular events.

2 September 2016 in Trials
Verified
Journal Article
Open access
PDF file
FMFernanda de Souza Nogueira Sardinha Mendes
Fernanda de Souza Nogueira Sardinha Mendes
Andrea Silvestre de SousaAndrea Silvestre de Sousa
Andrea Silvestre de Sousa
FSFernando Cesar de Castro Cesar Souza
Fernando Cesar de Castro Cesar Souza
VPVivian Liane Mattos Pinto
Vivian Liane Mattos Pinto
PSPaula Simplicio da Silva
Paula Simplicio da Silva
MMMauro Felippe Felix Mediano
Mauro Felippe Felix Mediano
The effects of exercise training on Chagas heart disease are still unclear. This study aimed to evaluate the effect of exercise training over functional capacity, cardiac function, quality of life, and biomarkers in Chagas heart disease. The PEACH study is a superiority randomized clinical trial which will include subjects who meet the following criteria: Chagas heart disease with a left ventricular ejection fraction below 45 % with or without heart failure symptoms; clinical stability in the last 3 months; adherence to clinical treatment; and age above 18 years. The exclusion criteria are: pregnancy; neuromuscular limitations; smoking; evidence of non-chagasic heart disease; systemic conditions that limit exercise practice or cardiopulmonary exercise test; unavailability to attend the center three times a week during the intervention period; and practitioners of regular exercise. The intervention group will perform an exercise training intervention three times per week during 6 months and will be compared to the control group without exercise. Both groups will undergo the same monthly pharmaceutical and nutritional counseling as well as standard medical treatment according to the Brazilian consensus on Chagas disease. The primary outcome is functional capacity based on peak exercise oxygen consumption during cardiopulmonary exercise testing. Secondary outcomes are: cardiac function; body composition; muscle respiratory strength; microvascular reactivity; cardiac rhythm abnormalities; autonomic function; biochemical; oxidative stress and inflammatory biomarkers; and quality of life. Subjects will be evaluated at baseline, and at 3 and 6 months after randomization. Thirty patients will be randomly assigned into exercise or control groups at a ratio of 1:1. Findings of the present study will be useful to determine if physical exercise programs should be included as an important additional therapy in the treatment of patients with Chagas heart disease. ClinicalTrials.gov ID: NCT02517632 (registered on 6 August 2015).

19 September 2018 in Trials
Verified
Journal Article
Open access
PDF file
MHMarcelo Teixeira Holanda
Marcelo Teixeira Holanda
MMMauro Felippe Felix Mediano
Mauro Felippe Felix Mediano
AHAlejandro Marcel Hasslocher-Moreno
Alejandro Marcel Hasslocher-Moreno
SXSérgio Salles Xavier
Sérgio Salles Xavier
RSRoberto Magalhães Saraiva
Roberto Magalhães Saraiva
TATania Cremonini Araújo-Jorge
Tania Cremonini Araújo-Jorge
Several studies evaluating clinical forms of chronic Chagas disease show that about one-third of patients present cardiac involvement. Heart failure, sudden death and cardioembolic stroke are the main mechanisms of death in Chagas heart disease. The impact of specific etiologic treatment on the prognosis of patients with chronic Chagas heart disease is very limited regardless of the presence or absence of heart failure. Patients with symptomatic Chagas heart disease present serum selenium (Se) levels lower than patients without Chagas heart disease. Moreover, Se supplementation in animal models showed promising results. The aim of this trial is to estimate the effect of Se treatment on prevention of heart disease progression in patients with Chagas cardiomyopathy. However, we had to introduce some protocol modifications in order to keep trial feasibility, as follows: the primary outcome was restricted to left ventricular ejection fraction as a continuous variable, excluding disease progression; the follow-up period was decreased from 5 years to 1 year, an adjustment that might increase the participation rate of our study; the superior age limit was increased from 65 to 75 years; and diabetes mellitus was no longer considered an exclusion criterion. All of these protocol modifications were extensively debated by the research team enrolled in the design, recruitment and conduction of the clinical trial to guarantee a high scientific quality. Clinical Trials.gov, NCT00875173 . Registered on 20 October 2008.